Stockreport

Royalty Pharma Reports First Quarter 2023 Results

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Net cash provided by operating activities (GAAP) of $1,034 million and Adjusted Cash Receipts(1) (non-GAAP) of $1,131 millionAnnounced transactions of up to $1.6 billion [Read more]